• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

选择性 Delta 蛋白激酶 C-丙酮酸脱氢酶激酶相互作用的磷酸化抑制剂:在体内心肌损伤中的应用。

Selective Phosphorylation Inhibitor of Delta Protein Kinase C-Pyruvate Dehydrogenase Kinase Protein-Protein Interactions: Application for Myocardial Injury in Vivo.

机构信息

Department of Chemical and Systems Biology, School of Medicine, Stanford University , Stanford, California 94305-5174, United States.

Nanjing, Jiangsu 210000, P.R. China.

出版信息

J Am Chem Soc. 2016 Jun 22;138(24):7626-35. doi: 10.1021/jacs.6b02724. Epub 2016 Jun 8.

DOI:10.1021/jacs.6b02724
PMID:27218445
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5065007/
Abstract

Protein kinases regulate numerous cellular processes, including cell growth, metabolism, and cell death. Because the primary sequence and the three-dimensional structure of many kinases are highly similar, the development of selective inhibitors for only one kinase is challenging. Furthermore, many protein kinases are pleiotropic, mediating diverse and sometimes even opposing functions by phosphorylating multiple protein substrates. Here, we set out to develop an inhibitor of a selective protein kinase phosphorylation of only one of its substrates. Focusing on the pleiotropic delta protein kinase C (δPKC), we used a rational approach to identify a distal docking site on δPKC for its substrate, pyruvate dehydrogenase kinase (PDK). We reasoned that an inhibitor of PDK's docking should selectively inhibit the phosphorylation of only PDK without affecting phosphorylation of the other δPKC substrates. Our approach identified a selective inhibitor of PDK docking to δPKC with an in vitro Kd of ∼50 nM and reducing cardiac injury IC50 of ∼5 nM. This inhibitor, which did not affect the phosphorylation of other δPKC substrates even at 1 μM, demonstrated that PDK phosphorylation alone is critical for δPKC-mediated injury by heart attack. The approach we describe is likely applicable for the identification of other substrate-specific kinase inhibitors.

摘要

蛋白激酶调节着众多的细胞过程,包括细胞生长、代谢和细胞死亡。由于许多激酶的一级序列和三维结构高度相似,因此开发仅针对一种激酶的选择性抑制剂具有挑战性。此外,许多蛋白激酶具有多功能性,通过磷酸化多种蛋白底物来介导不同的甚至相反的功能。在这里,我们着手开发一种仅针对其一个底物的选择性蛋白激酶磷酸化的抑制剂。我们专注于多功能性δ蛋白激酶 C(δPKC),使用合理的方法在其底物丙酮酸脱氢酶激酶(PDK)上确定了 δPKC 的一个远端对接位点。我们推断,PDK 对接的抑制剂应该选择性地抑制仅 PDK 的磷酸化,而不影响其他 δPKC 底物的磷酸化。我们的方法确定了一种对 δPKC 与 PDK 对接具有选择性的抑制剂,其体外 Kd 值约为 50 nM,对心脏损伤的 IC50 值约为 5 nM。该抑制剂即使在 1 μM 时也不会影响其他 δPKC 底物的磷酸化,证明 PDK 的磷酸化对于心肌梗塞引起的 δPKC 介导的损伤是至关重要的。我们所描述的方法可能适用于其他底物特异性激酶抑制剂的鉴定。

相似文献

1
Selective Phosphorylation Inhibitor of Delta Protein Kinase C-Pyruvate Dehydrogenase Kinase Protein-Protein Interactions: Application for Myocardial Injury in Vivo.选择性 Delta 蛋白激酶 C-丙酮酸脱氢酶激酶相互作用的磷酸化抑制剂:在体内心肌损伤中的应用。
J Am Chem Soc. 2016 Jun 22;138(24):7626-35. doi: 10.1021/jacs.6b02724. Epub 2016 Jun 8.
2
Engineered Substrate-Specific Delta PKC Antagonists to Enhance Cardiac Therapeutics.工程化底物特异性的 PKCδ 拮抗剂以增强心脏治疗效果。
Angew Chem Int Ed Engl. 2016 Dec 12;55(50):15672-15679. doi: 10.1002/anie.201605429. Epub 2016 Nov 17.
3
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) Protein-Protein Interaction Inhibitor Reveals a Non-catalytic Role for GAPDH Oligomerization in Cell Death.甘油醛-3-磷酸脱氢酶(GAPDH)蛋白-蛋白相互作用抑制剂揭示了GAPDH寡聚化在细胞死亡中的非催化作用。
J Biol Chem. 2016 Jun 24;291(26):13608-21. doi: 10.1074/jbc.M115.711630. Epub 2016 Apr 27.
4
Reperfusion-induced translocation of deltaPKC to cardiac mitochondria prevents pyruvate dehydrogenase reactivation.再灌注诱导的δ蛋白激酶C向心肌线粒体的易位可阻止丙酮酸脱氢酶的再激活。
Circ Res. 2005 Jul 8;97(1):78-85. doi: 10.1161/01.RES.0000173896.32522.6e. Epub 2005 Jun 16.
5
A novel inhibitor of pyruvate dehydrogenase kinase stimulates myocardial carbohydrate oxidation in diet-induced obesity.一种新型丙酮酸脱氢酶激酶抑制剂可刺激饮食诱导肥胖小鼠心肌碳水化合物氧化。
J Biol Chem. 2018 Jun 22;293(25):9604-9613. doi: 10.1074/jbc.RA118.002838. Epub 2018 May 8.
6
Activation of protein kinase C delta following cerebral ischemia leads to release of cytochrome C from the mitochondria via bad pathway.脑缺血后蛋白激酶 C 德尔塔的激活导致细胞色素 C 通过坏途径从线粒体释放。
PLoS One. 2011;6(7):e22057. doi: 10.1371/journal.pone.0022057. Epub 2011 Jul 15.
7
Impaired perfusion after myocardial infarction is due to reperfusion-induced deltaPKC-mediated myocardial damage.心肌梗死后灌注受损是由于再灌注诱导的δ蛋白激酶C介导的心肌损伤所致。
Cardiovasc Res. 2007 Mar 1;73(4):699-709. doi: 10.1016/j.cardiores.2006.12.011. Epub 2006 Dec 13.
8
Use of a novel method to find substrates of protein kinase C delta identifies M2 pyruvate kinase.使用一种新方法来寻找蛋白激酶Cδ的底物,从而鉴定出M2型丙酮酸激酶。
Int J Biochem Cell Biol. 2007;39(5):978-87. doi: 10.1016/j.biocel.2007.01.018. Epub 2007 Jan 24.
9
Cardioprotective mechanisms of PKC isozyme-selective activators and inhibitors in the treatment of ischemia-reperfusion injury.蛋白激酶C同工酶选择性激活剂和抑制剂在治疗缺血再灌注损伤中的心脏保护机制。
Pharmacol Res. 2007 Jun;55(6):523-36. doi: 10.1016/j.phrs.2007.04.005. Epub 2007 Apr 29.
10
δPKC interaction with the d subunit of F1Fo ATP synthase impairs energetics and exacerbates ischemia/reperfusion injury in isolated rat hearts.δ蛋白激酶C与F1Fo ATP合酶的d亚基相互作用会损害能量代谢,并加重离体大鼠心脏的缺血/再灌注损伤。
J Mol Cell Cardiol. 2015 Dec;89(Pt B):232-40. doi: 10.1016/j.yjmcc.2015.10.030. Epub 2015 Oct 28.

引用本文的文献

1
Applications of Graphene Field Effect Biosensors for Biological Sensing.石墨烯场效应生物传感器在生物传感中的应用。
Adv Biochem Eng Biotechnol. 2024;187:37-70. doi: 10.1007/10_2024_252.
2
Selective inhibitors targeting Fis1/Mid51 protein-protein interactions protect against hypoxia-induced damage in cardiomyocytes.靶向Fis1/Mid51蛋白-蛋白相互作用的选择性抑制剂可保护心肌细胞免受缺氧诱导的损伤。
Front Pharmacol. 2023 Dec 21;14:1275370. doi: 10.3389/fphar.2023.1275370. eCollection 2023.
3
An Update on Protein Kinases as Therapeutic Targets-Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases.

本文引用的文献

1
The ins and outs of selective kinase inhibitor development.选择性激酶抑制剂开发的来龙去脉。
Nat Chem Biol. 2015 Nov;11(11):818-21. doi: 10.1038/nchembio.1938.
2
Cationic PTD/CPP-mediated macromolecular delivery: charging into the cell.阳离子 PTD/CPP 介导的大分子递药系统:向细胞内输送。
Expert Opin Drug Deliv. 2015;12(10):1627-36. doi: 10.1517/17425247.2015.1046431. Epub 2015 May 20.
3
Development of pyruvate dehydrogenase kinase inhibitors in medicinal chemistry with particular emphasis as anticancer agents.医学化学中丙酮酸脱氢酶激酶抑制剂的开发,特别强调作为抗癌药物。
蛋白激酶作为治疗靶点的最新研究进展——第一部分:蛋白激酶 C 的激活及其在癌症和心血管疾病中的作用。
Int J Mol Sci. 2023 Dec 18;24(24):17600. doi: 10.3390/ijms242417600.
4
An Update on Protein Kinases as Therapeutic Targets-Part II: Peptides as Allosteric Protein Kinase C Modulators Targeting Protein-Protein Interactions.蛋白激酶作为治疗靶点的最新研究进展——第二部分:靶向蛋白-蛋白相互作用的别构蛋白激酶 C 调节剂肽。
Int J Mol Sci. 2023 Dec 15;24(24):17504. doi: 10.3390/ijms242417504.
5
Demonstration of the Early Cardiac Bioavailability of a Non-Specific Cell-Targeted Peptide Using Radionuclide-Based Imaging In Vivo.使用基于放射性核素的体内成像技术证明非特异性细胞靶向肽的早期心脏生物利用度。
Pharmaceuticals (Basel). 2023 May 31;16(6):824. doi: 10.3390/ph16060824.
6
De Novo Development of Mitochondria-Targeted Molecular Probes Targeting Pink1.靶向 Pink1 的线粒体靶向分子探针的从头开发。
Int J Mol Sci. 2022 May 28;23(11):6076. doi: 10.3390/ijms23116076.
7
A novel mRNA decay inhibitor abolishes pathophysiological cellular transition.一种新型mRNA衰变抑制剂可消除病理生理细胞转变。
Cell Death Discov. 2022 Jun 7;8(1):278. doi: 10.1038/s41420-022-01076-4.
8
Disrupting the MAD2L2-Rev1 Complex Enhances Cell Death upon DNA Damage.破坏 MAD2L2-Rev1 复合物可增强 DNA 损伤时的细胞死亡。
Molecules. 2022 Jan 19;27(3):636. doi: 10.3390/molecules27030636.
9
Myocardial Proteomics Based on Smart Fog Computing and Its Application in Sports.基于智能雾计算的心肌蛋白质组学及其在运动中的应用。
Comput Intell Neurosci. 2022 Feb 2;2022:1471916. doi: 10.1155/2022/1471916. eCollection 2022.
10
A Genetic Toggle for Chemical Control of Individual Plk1 Substrates.用于化学控制单个Plk1底物的基因开关。
Cell Chem Biol. 2020 Mar 19;27(3):350-362.e8. doi: 10.1016/j.chembiol.2020.01.007. Epub 2020 Feb 3.
Drug Discov Today. 2015 Sep;20(9):1112-9. doi: 10.1016/j.drudis.2015.03.012. Epub 2015 Apr 1.
4
Therapeutic applications of the cell-penetrating HIV-1 Tat peptide.细胞穿透 HIV-1 Tat 肽的治疗应用。
Drug Discov Today. 2015 Jan;20(1):76-85. doi: 10.1016/j.drudis.2014.09.017. Epub 2014 Sep 30.
5
Microwave-assisted synthesis of cyclic phosphopeptide on solid support.微波辅助在固相载体上合成环磷肽
Chem Biol Drug Des. 2015 Mar;85(3):300-5. doi: 10.1111/cbdd.12388. Epub 2014 Jul 24.
6
FFA-induced hepatic insulin resistance in vivo is mediated by PKCδ, NADPH oxidase, and oxidative stress.FFA 诱导的体内肝胰岛素抵抗是由 PKCδ、NADPH 氧化酶和氧化应激介导的。
Am J Physiol Endocrinol Metab. 2014 Jul 1;307(1):E34-46. doi: 10.1152/ajpendo.00436.2013. Epub 2014 May 13.
7
Myocardial steatosis and necrosis in atria and ventricles of rats given pyruvate dehydrogenase kinase inhibitors.给予丙酮酸脱氢酶激酶抑制剂的大鼠心房和心室中的心肌脂肪变性和坏死
Toxicol Pathol. 2014 Dec;42(8):1250-66. doi: 10.1177/0192623314530195. Epub 2014 Apr 17.
8
The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility.丙酮酸脱氢酶激酶在代谢灵活性中的关键作用。
Nutr Metab (Lond). 2014 Feb 12;11(1):10. doi: 10.1186/1743-7075-11-10.
9
Cyclic peptides as therapeutic agents and biochemical tools.环状肽作为治疗剂和生化工具。
Biomol Ther (Seoul). 2012 Jan;20(1):19-26. doi: 10.4062/biomolther.2012.20.1.019.
10
Protein kinase C inhibitors: a patent review (2008 - 2009).蛋白激酶 C 抑制剂:专利分析(2008-2009)。
Expert Opin Ther Pat. 2013 Oct;23(10):1297-315. doi: 10.1517/13543776.2013.805205. Epub 2013 Jun 25.